Replies to post #13618 on Viropro, Inc. (VPRO)

[bazirgani]

Viropro estimates the combined, aggregate realizable value of its biosimilars portfolio to be in the range of $33 million to $42 million, depending upon market dynamics of the individual products."
based on this current value and number of shares at 916 millions:
Share price baseline should be $ 0.0458